Skip to main content

Table 1 The demographic and clinical characteristics of PD patients

From: A survey of impulse control disorders in Parkinson’s disease patients in Shanghai area and literature review

Item mean ± SD Range
Number of cases 217  
Male, n(%) 120 (55.3 %)  
Age, year 67.15 ± 0.61 40-85
Disease duration, year 5.78 ± 4.32 1-23
H&Y stage 1.43 ± 0.55 1-4
Use of levodopa, n(%) 193 (88.9 %)  
Use of DA agonists, n(%) 101 (46.5 %)  
Levodopa, (mg/d) 494.94 ± 348.03 100-2825
DA agonist LED, (mg/d) 135.15 ± 66.8 50-300
TLED, (mg/d) 548.53 ± 382.12 50-3000
  1. Note:DA agonist-LED (DA-LED, mg/d) = piribedil (mg/d) × 1 + pramipexole (mg/d) × 100. Total LED (TLED, mg/d) = regular levodopa dose (mg/d) × 1 + levodopa CR dose (mg/d) × 0.75 + DA-LED, and plus [regular levodopa dose (mg/d) + CR levodopa dose(mg/d) × 0.75] × 0.33 if taking COMT-I [24]